Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma. This phase I study in patients with relapsed or progressive multiple myeloma assessed the safety and tolerability of escalating doses of carfilzomib in combination with lenali...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013-04, Vol.19 (8), p.2248-2256
Hauptverfasser:	NIESVIZKY, Ruben, MARTIN, Thomas G, BENSINGER, William I, ALSINA, Melissa, SIEGEL, David S, KUNKEL, Lori A, WONG, Alvin F, LEE, Susan, ORLOWSKI, Robert Z, WANG, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Dexamethasone - administration & dosage Dexamethasone - adverse effects Diarrhea - chemically induced Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Fatigue - chemically induced Female Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - pathology Neoplasm Recurrence, Local Neutropenia - chemically induced Oligopeptides - administration & dosage Oligopeptides - adverse effects Pharmacology. Drug treatments Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!